A5060973368- Blood groups and transfusion
- Erythrocyte Function and Pathophysiology
- Blood disorders and treatments
- Complement system in diseases
- Platelet Disorders and Treatments
- Hemoglobinopathies and Related Disorders
- Immunodeficiency and Autoimmune Disorders
- Chronic Lymphocytic Leukemia Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Acute Myeloid Leukemia Research
- COVID-19 Clinical Research Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Iron Metabolism and Disorders
- Hematological disorders and diagnostics
- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- Erythropoietin and Anemia Treatment
- Eosinophilic Disorders and Syndromes
- Long-Term Effects of COVID-19
- Lipid metabolism and disorders
- Chronic Myeloid Leukemia Treatments
- Neonatal Health and Biochemistry
- Blood properties and coagulation
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2016-2024
University College West Flanders
2023
KU Leuven
2023
Instytut Hematologii i Transfuzjologi
2023
United States Food and Drug Administration
2023
University of Milan
2019-2022
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2022
Ospedale Maggiore
2016
Evans syndrome (ES) is a rare condition, defined as the presence of 2 autoimmune cytopenias, most frequently hemolytic anemia and immune thrombocytopenia (ITP) rarely neutropenia. ES can be classified primary or secondary to various conditions, including lymphoproliferative disorders, other systemic diseases, immunodeficiencies, particularly in children. In adult ES, little known about clinical features, disease associations, outcomes. this retrospective international study, we analyzed 116...
Congenital hemolytic anemias (CHAs) are heterogeneous and rare disorders caused by alterations in structure, membrane transport, metabolism, or red blood cell production. The pathophysiology of these diseases, particular the rarest, is often poorly understood, easy-to-apply tools for diagnosis, clinical management, patient stratification still lacking. We report 3-years monocentric experience with a 43 genes targeted Next Generation Sequencing (t-NGS) panel diagnosis CHAs; 122 patients from...
Low-risk myelodysplastic syndromes (LR-MDS) are a very heterogeneous disease, with extremely variable clinical features and outcome. Therapeutic strategies still limited mainly consist of erythropoiesis-stimulating agents (ESAs) transfusion support. The contribution molecular lesions autoimmune phenomena to pathogenesis course, including leukemic evolution, is field open investigation. We analyzed data from cohort 226 patients LR-MDS followed at our center in the last 20 years, focusing on...
Immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA) show good responses to frontline steroids. About two-third of cases relapse require second-line treatment, including rituximab, mainly effective in AIHA, thrombopoietin-receptor agonists (TPO-RAs) ITP, while the use splenectomy progressively decreased due concerns for infectious/thrombotic complications. For those failing second line, immunosuppressants may be considered.The aim this study was evaluate efficacy cyclosporine...
Liver diseases remain unexplained in up to 30% of adult patients; genetic analysis could help establish the correct diagnosis. In six patients with cryptogenic liver disease, we performed whole-exome sequencing (WES) and evaluated individual predisposition progressive fatty disease by polygenic risk scores (PRS). one patient, WES was allowed diagnose Hermansky-Pudlak syndrome. other two patients, variants LDLRAP1/MSH6 ALDOB genes were identified, contributing explaining clinical presentation...
Abstract Data concerning the efficacy of SARS-CoV-2 vaccines in patients with non-oncological hematologic conditions are lacking. These include autoimmune cytopenias (autoimmune hemolytic anemia AIHA, immune thrombocytopenia ITP, and neutropenia), bone marrow failure syndromes (aplastic anemia, low risk myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria). may relapse/reactivate after COVID-19 infection vaccine. Moreover, they mainly handled immunosuppressive drugs that hamper...
Hematologic patients show lower responses to SARS-CoV-2 vaccines, but predictors of seroconversion are lacking. In this prospective cohort study, hematologic undergoing mRNA vaccination at a single center in Milan, Italy, were sampled for anti-Spike and anti-Nucleocapsid IgG titer 5 ± 1 weeks 3 months from the second vaccine dose. Patients (N = 393) received either BNT162b2 (Pfizer-BioNTech, 48%) or MRNA-1273 (Moderna, 52%), 284 (72%) seroconverted 100% persisted months. Non-response was...